FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4291222812> ?p ?o ?g. }

• W4291222812 endingPage "486" @default.
• W4291222812 startingPage "471" @default.
• W4291222812 abstract "The heat shock protein 27 (Hsp27) has emerged as a principal factor of the castration-resistant prostate cancer (CRPC) progression. Also, an antisense oligonucleotide (ASO) against Hsp27 (OGX-427 or apatorsen) has been assessed in different clinical trials. Here, we illustrate that Hsp27 highly regulates the expression of the human DEAD-box protein 5 (DDX5), and we define DDX5 as a novel therapeutic target for CRPC treatment. DDX5 overexpression is strongly correlated with aggressive tumor features, notably with CRPC. DDX5 downregulation using a specific ASO-based inhibitor that acts on DDX5 mRNAs inhibits cell proliferation in preclinical models, and it particularly restores the treatment sensitivity of CRPC. Interestingly, through the identification and analysis of DDX5 protein interaction networks, we have identified some specific functions of DDX5 in CRPC that could contribute actively to tumor progression and therapeutic resistance. We first present the interactions of DDX5 and the Ku70/80 heterodimer and the transcription factor IIH, thereby uncovering DDX5 roles in different DNA repair pathways. Collectively, our study highlights critical functions of DDX5 contributing to CRPC progression and provides preclinical proof of concept that a combination of ASO-directed DDX5 inhibition with a DNA damage-inducing therapy can serve as a highly potential novel strategy to treat CRPC. The heat shock protein 27 (Hsp27) has emerged as a principal factor of the castration-resistant prostate cancer (CRPC) progression. Also, an antisense oligonucleotide (ASO) against Hsp27 (OGX-427 or apatorsen) has been assessed in different clinical trials. Here, we illustrate that Hsp27 highly regulates the expression of the human DEAD-box protein 5 (DDX5), and we define DDX5 as a novel therapeutic target for CRPC treatment. DDX5 overexpression is strongly correlated with aggressive tumor features, notably with CRPC. DDX5 downregulation using a specific ASO-based inhibitor that acts on DDX5 mRNAs inhibits cell proliferation in preclinical models, and it particularly restores the treatment sensitivity of CRPC. Interestingly, through the identification and analysis of DDX5 protein interaction networks, we have identified some specific functions of DDX5 in CRPC that could contribute actively to tumor progression and therapeutic resistance. We first present the interactions of DDX5 and the Ku70/80 heterodimer and the transcription factor IIH, thereby uncovering DDX5 roles in different DNA repair pathways. Collectively, our study highlights critical functions of DDX5 contributing to CRPC progression and provides preclinical proof of concept that a combination of ASO-directed DDX5 inhibition with a DNA damage-inducing therapy can serve as a highly potential novel strategy to treat CRPC." @default.
• W4291222812 created "2022-08-13" @default.
• W4291222812 creator A5002637615 @default.
• W4291222812 creator A5013015930 @default.
• W4291222812 creator A5023454713 @default.
• W4291222812 creator A5034110828 @default.
• W4291222812 creator A5035672550 @default.
• W4291222812 creator A5041435318 @default.
• W4291222812 creator A5052710823 @default.
• W4291222812 creator A5056591938 @default.
• W4291222812 creator A5056634083 @default.
• W4291222812 creator A5062125605 @default.
• W4291222812 creator A5064510604 @default.
• W4291222812 creator A5069536845 @default.
• W4291222812 creator A5073384497 @default.
• W4291222812 creator A5082910071 @default.
• W4291222812 creator A5088858043 @default.
• W4291222812 creator A5091721810 @default.
• W4291222812 date "2023-02-01" @default.
• W4291222812 modified "2023-10-14" @default.
• W4291222812 title "DDX5 mRNA-targeting antisense oligonucleotide as a new promising therapeutic in combating castration-resistant prostate cancer" @default.
• W4291222812 cites W1525230438 @default.
• W4291222812 cites W1930591242 @default.
• W4291222812 cites W1965917470 @default.
• W4291222812 cites W1966003468 @default.
• W4291222812 cites W1976830478 @default.
• W4291222812 cites W1984143603 @default.
• W4291222812 cites W1992473001 @default.
• W4291222812 cites W2002900988 @default.
• W4291222812 cites W2005202590 @default.
• W4291222812 cites W2006285635 @default.
• W4291222812 cites W2034710772 @default.
• W4291222812 cites W2035618305 @default.
• W4291222812 cites W2047137409 @default.
• W4291222812 cites W2065395616 @default.
• W4291222812 cites W2082496903 @default.
• W4291222812 cites W2088819616 @default.
• W4291222812 cites W2102421724 @default.
• W4291222812 cites W2116807128 @default.
• W4291222812 cites W2119036448 @default.
• W4291222812 cites W2121982512 @default.
• W4291222812 cites W2129297473 @default.
• W4291222812 cites W2137822257 @default.
• W4291222812 cites W2139442487 @default.
• W4291222812 cites W2142855214 @default.
• W4291222812 cites W2148043260 @default.
• W4291222812 cites W2156602474 @default.
• W4291222812 cites W2164185011 @default.
• W4291222812 cites W2171030481 @default.
• W4291222812 cites W2314144775 @default.
• W4291222812 cites W2324289718 @default.
• W4291222812 cites W2345499896 @default.
• W4291222812 cites W2756041018 @default.
• W4291222812 cites W2756782642 @default.
• W4291222812 cites W2787093671 @default.
• W4291222812 cites W2800358055 @default.
• W4291222812 cites W2800659481 @default.
• W4291222812 cites W2889646458 @default.
• W4291222812 cites W2899937601 @default.
• W4291222812 cites W2944545583 @default.
• W4291222812 cites W2952073075 @default.
• W4291222812 cites W2964818755 @default.
• W4291222812 cites W2971366905 @default.
• W4291222812 cites W2998094044 @default.
• W4291222812 cites W2999013831 @default.
• W4291222812 cites W3042892878 @default.
• W4291222812 cites W3047599202 @default.
• W4291222812 cites W3048788919 @default.
• W4291222812 cites W3088887338 @default.
• W4291222812 cites W3106573323 @default.
• W4291222812 cites W3129892394 @default.
• W4291222812 cites W3164967630 @default.
• W4291222812 cites W3177876230 @default.
• W4291222812 cites W3201570266 @default.
• W4291222812 cites W3210225758 @default.
• W4291222812 cites W4243979784 @default.
• W4291222812 doi "https://doi.org/10.1016/j.ymthe.2022.08.005" @default.
• W4291222812 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35965411" @default.
• W4291222812 hasPublicationYear "2023" @default.
• W4291222812 type Work @default.
• W4291222812 citedByCount "6" @default.
• W4291222812 countsByYear W42912228122022 @default.
• W4291222812 countsByYear W42912228122023 @default.
• W4291222812 crossrefType "journal-article" @default.
• W4291222812 hasAuthorship W4291222812A5002637615 @default.
• W4291222812 hasAuthorship W4291222812A5013015930 @default.
• W4291222812 hasAuthorship W4291222812A5023454713 @default.
• W4291222812 hasAuthorship W4291222812A5034110828 @default.
• W4291222812 hasAuthorship W4291222812A5035672550 @default.
• W4291222812 hasAuthorship W4291222812A5041435318 @default.
• W4291222812 hasAuthorship W4291222812A5052710823 @default.
• W4291222812 hasAuthorship W4291222812A5056591938 @default.
• W4291222812 hasAuthorship W4291222812A5056634083 @default.
• W4291222812 hasAuthorship W4291222812A5062125605 @default.
• W4291222812 hasAuthorship W4291222812A5064510604 @default.
• W4291222812 hasAuthorship W4291222812A5069536845 @default.
• W4291222812 hasAuthorship W4291222812A5073384497 @default.
• W4291222812 hasAuthorship W4291222812A5082910071 @default.

• next